A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts

Autor: Howard L. Parnes, Angelo M. De Marzo, Ian M. Thompson, Charles G. Drake, Scott M. Lippman, Eric A. Klein, Elizabeth A. Platz, John R. Barber, Ibrahim Kulac, M. Scott Lucia, Phyllis J. Goodman, Corinne E. Joshu, Catherine M. Tangen, William G. Nelson
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Aging
Epidemiology
Medical and Health Sciences
Cohort Studies
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
Prostate
Prospective Studies
Prospective cohort study
Cancer
Selenium and Vitamin E Cancer Prevention Trial
medicine.diagnostic_test
Prostate Cancer
Single Nucleotide
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Finasteride
Risk
Urologic Diseases
medicine.medical_specialty
Clinical Trials and Supportive Activities
Urology
Polymorphism
Single Nucleotide
Article
03 medical and health sciences
Clinical Research
Biopsy
medicine
Humans
Prostate Cancer Prevention Trial
Polymorphism
Aged
Inflammation
Gynecology
business.industry
Prevention
Prostatic Neoplasms
medicine.disease
Good Health and Well Being
030104 developmental biology
chemistry
Chronic Disease
business
Zdroj: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 26, iss 10
ISSN: 1538-7755
1055-9965
DOI: 10.1158/1055-9965.epi-17-0503
Popis: Background: We leveraged two trials to test the hypothesis of an inflammation–prostate cancer link prospectively in men without indication for biopsy. Methods: Prostate Cancer Prevention Trial (PCPT) participants who had an end-of-study biopsy performed per protocol that was negative for cancer and who subsequently enrolled in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) were eligible. We selected all 100 cases and sampled 200 frequency-matched controls and used PCPT end-of-study biopsies as “baseline.” Five men with PSA > 4 ng/mL at end-of-study biopsy were excluded. Tissue was located for 92 cases and 193 controls. We visually assessed inflammation in benign tissue. We estimated ORs and 95% confidence intervals (CI) using logistic regression adjusting for age and race. Results: Mean time between biopsy and diagnosis was 5.9 years. In men previously in the PCPT placebo arm, 78.1% of cases (N = 41) and 68.2% of controls (N = 85) had at least one baseline biopsy core (∼5 evaluated per man) with inflammation. The odds of prostate cancer (N = 41 cases) appeared to increase with increasing mean percentage of tissue area with inflammation, a trend that was statistically significant for Gleason sum 0– Conclusions: Benign tissue inflammation was positively associated with prostate cancer. Impact: This first prospective study of men without biopsy indication supports the hypothesis that inflammation influences prostate cancer development. Cancer Epidemiol Biomarkers Prev; 26(10); 1549–57. ©2017 AACR.
Databáze: OpenAIRE
Externí odkaz: